Member Info for Rocket79

Information obtained from single-cell RNA sequencing of bone marrow CTCs could be used in the near future to develop personalized treatment strategies for each patient. For example,

If CTCs are found in the bone marrow examination at the time of surgery and their genetic analysis shows markers associated with stem cell characteristics and treatment resistance, the patient may be considered for closer follow-up or early adjuvant therapy (extending hormonal therapy or targeted therapy) even if metastases have not yet appeared on imaging studies. Patients with specific gene expression patterns identified in bone marrow CTCs have been observed to have a higher risk of early distant relapse, so it may be possible to select high-risk patients and adjust the intensity of treatment.​

If the correlation between CTC genetic profiles and optimal treatment is accumulated through future multi-institutional clinical studies, it could be utilized for precision medicine according to the “CTC genetic fingerprint” of each cancer patient

Signposted from elsewhere :

Https://www.dowbiomedica.co.kr/en/sub/product/line.asp#mole

The Product Line tab drop down menu details a breakdown of Molecular Diagnostics & under CTC's there's a small British MedTech Company . .

Https://m.blog.naver.com/PostView.naver?blogId=dowbiomedica&logNo=223783706205&proxyReferer=hxxps:%2F%2Fwww.linkedin.com%2F&trackingCode=external

I agree and Illumina will be using Angles Parsortix as this gives them an edge over competition.

Good news

News coming just need some patience

E Mail from IR. News,coming

Hi...

AZ did push the timeline out on the DDR work for internal scheduling purposes, but that and the other contracts are all progressing well. We will of course update the market when there are material changes.

Kind regards

Ian

New tweet from Angle

https://x.com/Parsortix/status/1895493037201187153

HTTPS://angleplc.com/product-solutions/cellkeepslide/

'...CellKeep CTC retention rate of 77% significantly outperforming a market alternative at 30%.'

Question...Will those currently using 'market alternatives'....upgrade to CellKeep? I would say for sure...

Https://illumina.postclickmarketing.com/MOxFebruaryNewsletter

I note the references to the PARSORTIX study:

• Digoxin for reduction of CTC cluster size in metastatic breast cancer: a proof-of-concept trial

• https://www.nature.com/articles/s41591-024-03486-6#Sec1

-

Q - why would ILLUMINA reference this study on their webpage relating to single-cell sequencing?

• Introducing Illumina Single Cell 3’ RNA Prep, a highly efficient, affordable, and accurate workflow for single-cell analysis. Accessible for more labs with an easy, scalable, and microfluidics-free workflow, researchers can now undertake larger and more varied multiomic studies to scale experiments from hundreds to millions of cells.

• https://www.illumina.com/products/by-type/sequencing-kits/library-prep-kits/single-cell-rna-prep.html?media=9089239&utm_medium=email&catt=email_Email_Campaign_Internal

-

Throw in the mix ILLUMINAs recent news on collaboration with BROAD CLINICAL LABS to usher in a ‘new era of drug discovery’ it gets even more interesting. WHY?

A - Because this collaboration specifically names the ILLUMINA Single Cell 3' RNA Prep kit.

• See “The capabilities we're building, like combining Perturb-seq with ILLUMINA SINGLE CELL 3' RNA PREP, will SUPPORT rapid and consistent data generation like we've demonstrated in the whole genome space, giving the research community the ability to create billion-cell atlas studies to make the next discoveries."

• https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=383b9322-6cef-4fdd-8099-05a6f6904872

So…

The ILLUMINA Single Cell 3' RNA Prep threads the needle!!!

-

Q - If ILLUMINA are referencing the PARSORTIX study does this confirm ILLUMINA ‘already’ sees PARSORTIX as a viable upstream component for its single-cell workflows?

or

Q - Does the fact that ILLUMINA “EXPLICITLY” references its Single Cell 3’ RNA Prep Kit on the same page as a study using PARSORTIX suggest that ILLUMINA sees value in “COMBINING” CTC capture with single-cell sequencing?

-

It is SIGNIFICANT that ILLUMINA and BROAD are “expanding” single-cell research at “SCALE” - They emphasise functional genomics, disease modeling, and drug discovery - all of which “ALIGN” with the kind of insights CTCs provide.

Hmmm!

-

Q - Would it make sense for ILLUMINA and BROAD to integrate PARSORTIX into their Single-Cell Workflow?

Q - Could this lead to a “FORMALISED” workflow where PARSORTIX is positioned as a “STANDARD” upstream sample prep solution for single-cell sequencing?

-

HOW CAN ANGLE MAKE DOSH?:

Q - We know ILLUMINA and BROAD “WANT” scalable single-cell workflows. If PARSORTIX is integrated into their pipeline, “COULD” ANGLE license it and EARN ROYALTIES on EVERY SAMPLE processed?

Because - this would be similar to “how” ILLUMINA structures licensing deals with other sample prep and bioinformatics companies!

Hmmm!

-

FINAL THOUGHT:

For me, t

May be of interest & familiar :

This from Illumina

"Multiomics in action

Publication highlights from the research community

Liquid Biopsy

Single-cell/Spatial

Microbiomics

Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial

This study, by Nicola Aceto's team in Zurich, illustrates a great approach to better understand the role of metastasis in cancer-related death. Compared to individual circulating tumor cells (CTCs), CTC clusters demonstrate higher metastatic potential and thus significant impact on cancer progression. In this publication, the effect of Na+/K+ ATPase digoxin was evaluated in a proof-of-concept study in women with metastatic breast cancer. Results showed CTC cluster size reduction, while CTC transcriptome profiling revealed downregulation of specific genes upon treatment with digoxin.

Learn more about the Illumina portfolio for analyzing liquid biopsy samples.

Publication LinkOpens in a new window."

Https://illumina.postclickmarketing.com/MOxFebruaryNewsletter

Https://www.youtube.com/watch?v=olB0eo_iYcA

Https://www.youtube.com/watch?v=-bU7dwjGBKU&t=1s

I urge all posters to filter fevertree and TGTD i have so bb is alot better. They have no clue look at their posting history.

I dought TGTD has big short as only has tip money from his deliveroo deliveries. Maybe a small position lol. Just filter the clowns looking at posts they are novice traders.

Or the same person...

Buy and Hold dont sell you shares cheap. 48p broker note.

Trinity Delta view: ANGLE’s collaboration with Illumina, the global leader in next-generation sequencing systems and assays, has significant potential to expand the Parsortix commercial opportunity. Liquid biopsy centred on ctDNA analysis is already widely adopted and these recent studies confirm that Parsortix-enabled dual CTC-DNA and ctDNA analysis can provide additional complementary information for cancer diagnosis and longitudinal monitoring. Establishing an optimised end-to-end workflow for simultaneous analysis is a key step towards supporting Illumina’s customers and offering CTC analysis for DNA dual analysis NGS. In our view, these developments should also help secure new Pharma Services contracts – a key strategic objective for ANGLE – by providing these customers with a sample-to-answer solution that delivers comprehensive molecular insights across many cancers to help guide targeted therapy. Our ANGLE valuation is £155m, equivalent to 48p per share.

TGTD posting inbetween his deliveries for deliveroo. Time for the filter as has no clue.

Buying now relentless and all one US stock market opened. Definitely not a PI with the size of buys. Illumina stake building?

Massive buys going through. Either partnership with Illumina or news on contracts with AstraZeneca imo

I highlight IMPORTANCE TO BITH COMPANIES. Illumina will take Angle plc inhouse at a massive premium imo

"As a result of these positive findings and their IMPORTANCE to both companies, Illumina has assigned their entire European Association for Cancer Research (EACR) webinar to ANGLE's findings. "

One thing you can be certain of is that Illumina is not marketing Parsortix out of kindness. There is clear commercial motive. I suspect it will market its customer base, do its sums and make a decision whether to take Angle in-house or continue the romance a while longer while the market and the technology develops. Either way won’t do shareholders any harm.

Trinity Delta view: ANGLE’s collaboration with Illumina, the global leader in next-generation sequencing systems and assays, has significant potential to expand the Parsortix commercial opportunity. Liquid biopsy centred on ctDNA analysis is already widely adopted and these recent studies confirm that Parsortix-enabled dual CTC-DNA and ctDNA analysis can provide additional complementary information for cancer diagnosis and longitudinal monitoring. Establishing an optimised end-to-end workflow for simultaneous analysis is a key step towards supporting Illumina’s customers and offering CTC analysis for DNA dual analysis NGS. In our view, these developments should also help secure new Pharma Services contracts – a key strategic objective for ANGLE – by providing these customers with a sample-to-answer solution that delivers comprehensive molecular insights across many cancers to help guide targeted therapy. Our ANGLE valuation is £155m, equivalent to 48p per share.